Evidence map›Paper›PMID 23091108›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Hiltrud Brauch, Werner Schroth, Matthew P Goetz, Thomas E Mürdter, Stefan Winter, James N Ingle, Matthias Schwab, Michel Eichelbaum

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Germline variants in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Hiltrud BrauchDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Werner Schroth
Matthew P Goetz
Thomas E Mürdter
Stefan Winter
James N Ingle
Matthias Schwab
Michel Eichelbaum

Funding

Tamoxifen biotransformation pathway pharmacogenomicsR01CA133049 · NCI · MAYO CLINIC ROCHESTER · PI GOETZ, MATTHEW PHILIP · 2008 to 2013
$2.3M
NCI NIH HHS R01 CA133049
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardenolidesCytochrome P-450 CYP2D6FemaleHumansPolymorphism, GeneticPostmenopauseSaponinsTamoxifenafimoxifeneAntineoplastic Agents, HormonalCardenolidesCytochrome P-450 CYP2D6digoxin-like factorsSaponinsTamoxifen

Identifiers

PMID23091108
PMCPMC3731938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.